Morepen Labs.
NSE: MOREPENLAB · Pharmaceuticals
Snapshot
Unlock Morepen Labs.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Morepen Laboratories is a pharmaceutical company that manufactures active pharmaceutical ingredients (APIs), branded formulations, and a diverse range of home health diagnostic devices. The company operates across both domestic and international markets, offering products ranging from life-saving drugs to over-the-counter wellness solutions.
Business Model
The company generates revenue through the sale of APIs to global pharmaceutical manufacturers, the distribution of branded formulations, and the retail of medical devices under the Dr. Morepen brand. It further leverages contract manufacturing and brand-sharing partnerships to diversify its income streams.
- Export reach:75 countries
- Incorporation year:1984
Growth Outlook
Growth is driven by the expansion of the point-of-care medical device portfolio and the strengthening of its API manufacturing capabilities. The company continues to focus on its Dr. Morepen brand to capture increasing demand in the Indian over-the-counter healthcare market.
Key Risks
- Regulatory Compliance. The company faces stringent quality control and manufacturing standards from global health authorities, where non-compliance could lead to export bans.
- Market Competition. Intense competition in the generic drug and medical device sectors may exert pressure on profit margins.
- Currency Volatility. As a significant exporter to 75 countries, the company is exposed to fluctuations in foreign exchange rates that can impact profitability.
- Supply Chain Disruptions. Dependence on raw material imports for API manufacturing makes the company vulnerable to global supply chain bottlenecks.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Morepen Labs. and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,806 Cr
TTM · consolidated
NET PROFIT
₹95 Cr
TTM · consolidated
EPS
₹1.73
TTM · consolidated
RETURN ON EQUITY
8.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
10.3%
TTM · consolidated
P/E
35.2x
Q4 FY26 · consolidated
EV/EBITDA
23.8x
Q4 FY26 · consolidated
EBITDA MARGIN
8.1%
TTM · consolidated
NET PROFIT MARGIN
3.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Morepen Labs.MOREPENLAB | 2,011 | 35.16 | 23.79 | -0.3% | 8.1% | 8.0% | 10.3% | -3.9% |
Bliss GVS PharmaBLISSGVS | 2,193 | 41.29 | 22.41 | 14.5% | 25.6% | 12.4% | 17.4% | +219.3% |
Unichem Laboratories LimitedUNICHEMLAB | 2,111 | 16.84 | 18.17 | 8.5% | 11.1% | 10.0% | 12.2% | -6.3% |
Panacea BiotecPANACEABIO | 2,027 | -640.85 | 279.46 | 14.4% | 1.9% | -0.9% | -0.1% | +30.3% |
HikalHIKAL | 1,988 | -207.43 | 15.31 | -7.9% | 13.6% | -3.9% | -0.9% | -32.4% |
Solara ActiveSOLARA | 1,953 | -344.08 | 17.88 | 6.6% | 14.1% | -0.7% | 6.6% | -16.5% |
As of Q4 FY26
Financials
Morepen Labs.
NSE: MOREPENLAB · Pharmaceuticals
Snapshot
Unlock Morepen Labs.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Morepen Laboratories is a pharmaceutical company that manufactures active pharmaceutical ingredients (APIs), branded formulations, and a diverse range of home health diagnostic devices. The company operates across both domestic and international markets, offering products ranging from life-saving drugs to over-the-counter wellness solutions.
Business Model
The company generates revenue through the sale of APIs to global pharmaceutical manufacturers, the distribution of branded formulations, and the retail of medical devices under the Dr. Morepen brand. It further leverages contract manufacturing and brand-sharing partnerships to diversify its income streams.
- Export reach:75 countries
- Incorporation year:1984
Growth Outlook
Growth is driven by the expansion of the point-of-care medical device portfolio and the strengthening of its API manufacturing capabilities. The company continues to focus on its Dr. Morepen brand to capture increasing demand in the Indian over-the-counter healthcare market.
Key Risks
- Regulatory Compliance. The company faces stringent quality control and manufacturing standards from global health authorities, where non-compliance could lead to export bans.
- Market Competition. Intense competition in the generic drug and medical device sectors may exert pressure on profit margins.
- Currency Volatility. As a significant exporter to 75 countries, the company is exposed to fluctuations in foreign exchange rates that can impact profitability.
- Supply Chain Disruptions. Dependence on raw material imports for API manufacturing makes the company vulnerable to global supply chain bottlenecks.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Morepen Labs. and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,806 Cr
TTM · consolidated
NET PROFIT
₹95 Cr
TTM · consolidated
EPS
₹1.73
TTM · consolidated
RETURN ON EQUITY
8.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
10.3%
TTM · consolidated
P/E
35.2x
Q4 FY26 · consolidated
EV/EBITDA
23.8x
Q4 FY26 · consolidated
EBITDA MARGIN
8.1%
TTM · consolidated
NET PROFIT MARGIN
3.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26